Business Wire

CA-NETAPP

Share
NetApp Fights Ransomware in Real-Time with Built-In Artificial Intelligence on Enterprise Storage and Enhanced Cyber-Resiliency Solutions

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced cyber-resiliency capabilities that will equip customers to better protect and recover their data in the face of ransomware threats. NetApp is one of the first to integrate artificial intelligence (AI) and machine learning (ML) directly into enterprise primary storage to fight ransomware in real-time. The NetApp cyber-resiliency capabilities protect both primary and secondary data for organizations whether it is stored on-premises or in the cloud.

Cybercriminals are increasingly aiming ransomware attacks at critical infrastructure and supply chains where operational disruptions can cost millions of dollars, according to Forrester. As a result, 87 percent of C-suite and board-level executives ranked ransomware as a high, or the top, priority for their organization, according to the NetApp 2023 Data Complexity report. When cybercriminals breach perimeters, networks, and identities storage becomes the last line of defense for organizations’ most critical data. With the threat of ransomware looming, organizations need solutions that not only protect their data but also quickly recover lost data and return to normal operations. NetApp is updating its cyber-resiliency solutions and leveraging the power of AI to give customers confidence that their data will be safe and accessible when they need it.

“NetApp is taking an aggressive and proactive approach to protecting our customers’ data against cyber threats using artificial intelligence. We are the first storage vendor to explicitly and financially guarantee our data storage offerings against ransomware,” said Mignona Cote, CSO at NetApp. “Today, we are furthering that leadership with updates that make defending data comprehensive, continuous, and simple for our customers.”

NetApp is focused on designing data storage and management systems that maximize data protection and security while meeting data governance and compliance standards, with new updates that include:

  • ONTAP Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI) will spearhead the next generation of real-time enterprise storage ransomware protection, giving increased accuracy and performance required to detect and mitigate new, more sophisticated cyber threats. NetApp pioneered autonomous real-time detection of ransomware directly in primary enterprise storage three years ago. Now, NetApp will be leading the charge to use adaptive AI/ML models built directly into enterprise primary storage to look at file-level signals in real-time to detect even the newest ransomware attacks with planned 99%+ precision and recall. NetApp will be offering the first technology preview of ARP/AI within the next quarter.
  • NetApp BlueXP Ransomware Protection, now in public preview, provides a single control plane to intelligently coordinate and execute an end-to-end, workload-centric ransomware defense. Customers can now identify and protect critical workload data with a single click, accurately and automatically detect and respond to a potential attack, and recover workloads within minutes, safeguarding their valuable data and minimizing costly disruption.
  • Application-Aware Ransomware Protection via NetApp SnapCenter 5.0 offers immutable ransomware protection for applications. SnapCenter will now apply NetApp's leading ransomware protection technologies, previously used with unstructured data, to application-consistent backup. SnapCenter 5.0 includes support for key ONTAP features like tamperproof Snapshot copy locking, SnapLock protected volumes, and SnapMirror Business Continuity to enable more robust data protection for applications and virtual machines. SnapCenter 5.0 supports protection of applications on-premises with NetApp AFF, ASA, and FAS, as well as in the cloud.
  • NetApp BlueXP Disaster Recovery, now generally available, offers seamless integration with VMware infrastructure and provides storage options for both on-premises and major public cloud environments. This comprehensive solution eliminates the need for separate standby disaster recovery (DR) infrastructure, reducing costs. With NetApp BlueXP disaster recovery, failover and failback processes are simplified, allowing smooth transitions from on-premises VMware infrastructure to the public cloud or to an on-premises data center.
  • NetApp Keystone Ransomware Recovery Guarantee extends NetApp’s current Ransomware Recovery Guarantee to our leading storage-as-a-service offering, NetApp Keystone. With this guarantee, NetApp will warrant snapshot data recovery in the event of a ransomware attack. If snapshot data copies can’t be recovered through NetApp, we will offer compensation*.

“Today’s cybersecurity teams face the monumental task of protecting their companies’ data from ever-evolving threats, especially ransomware,” said Archana Venkatraman, Research Director, Cloud Data Management, IDC. “NetApp’s approach of delivering a secure, unified storage infrastructure makes storage foundational for ransomware protection and reduces the burden on cybersecurity teams. Companies looking to fortify their cyber resiliency and shifting protection left will increasingly look to vendors that take a secure-by-design approach and develop unified storage and data services.”

“Using NetApp in our Advanced Technology Center, we significantly simplified our replication process for VMware virtual machines and their underlying datastores to meet or exceed recovery benchmarks,” said Derek Elbert, Solutions Architect at WWT. “With NetApp’s solutions, we successfully established the recovery policies for cloud volumes workloads or virtual machines with no existing DR strategy, managing everything through NetApp BlueXP. This transforms how we operate disaster recovery for VMware.”

“To store sensitive genomics and health data, we have to use the right technology with layers of security built in,” said Mark Cowley, Deputy Director at Children’s Cancer Institute. “With NetApp, we can be very confident that we are sharing the right data only to authorized researchers. The last line of defense is your weakest web-based system, so we’ve implemented role-based access and added resilience to all of our tools.”

The latest cyber resiliency updates from NetApp empower organizations to proactively address cybersecurity threats in complex hybrid and multicloud environments, leveraging AI to identify threats and prevent disruptions to their operations.

To learn more about the NetApp cyber-resiliency offerings visit: https://www.netapp.com/cyber-resilience/

*Specific terms and conditions will apply. Customers must apply for coverage by the guarantee.

Additional Resources

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305981204/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye